Related Experiment Videos
The NMDA receptor NR2B subunit: a valid therapeutic target for multiple CNS pathologies.
1Sunderland Pharmacy School, University of Sunderland, Sunderland, Tyne and Wear SR2 3SD, UK. paul.chazot@sunderland.ac.uk
Current Medicinal Chemistry
|February 18, 2004
Summary
The N-methyl-D-aspartate receptor 2B (NMDAR2B) subunit shows therapeutic potential for CNS disorders. Advanced drug development and structural insights are improving targeted treatments for conditions like pain and dementia.
Area of Science:
- Neuroscience
- Pharmacology
- Drug Discovery
Background:
- The NMDAR2B subunit is a key therapeutic target for various central nervous system (CNS) pathologies.
- Conditions include pain, stroke, head trauma, dyskinesias, and dementias.
Purpose of the Study:
- To review the therapeutic potential of targeting the NMDAR2B subunit.
- To discuss advancements in developing selective NMDAR2B antagonists.
Main Methods:
- Review of pharmaceutical research and development for NMDAR2B-targeting compounds.
- Analysis of structural data for the ifenprodil binding site.
- Consideration of receptor localization and post-translational modifications.
Main Results:
- A significant collection of chemical leads targeting the NR2B subunit has been developed.
- Structural templates for the ifenprodil binding site are available, aiding structure-activity relationship studies.
- Extrasynaptic localization and tyrosine phosphorylation of NR2B receptors are recognized for their therapeutic importance.
Conclusions:
- Second and third-generation NR2B compounds demonstrate superior preclinical and clinical data.
- This improvement is attributed to enhanced subtype selectivity, unique mechanisms of action, and specific cellular localization of NR2B receptors.